on VALBIOTIS (EPA:ALVAL)
Valbiotis Wins Double "Best Pharma Product 2027" Award
Valbiotis SA has been honored with a double "Best Pharma Product 2027" award for its innovative solutions, ValbiotisPRO® Cholestérol and ValbiotisPRO® Santé Métabolique. This recognition reflects ten years of dedicated research and development, supported by rigorous clinical studies. The awards were granted following real-life testing by independent consumers, signifying a strong endorsement of their efficacy.
Both products are strategically positioned in two promising French markets. Significant regulatory changes in the cholesterol supplement segment and growth in the "Metabolism and Nutrition" market present new opportunities. These accolades enhance Valbiotis' visibility and credibility, bolstering its commercial rollout strategy in pharmacies.
The recognition showcases Valbiotis' commitment to scientific excellence and innovation in cardiometabolic health. The company's efforts are backed by international scientific recognition and substantial investment in research and development. As Valbiotis continues to solidify its market presence, these awards become pivotal in strengthening consumer trust and expanding market reach.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news